Monopar Therapeutics 8-K, filed Jun 1, 2021
Monopar Therapeutics (MNPR)
8-K
2021-06-01
For: 2021-06-01
View Original
Added on
July 04, 2026
About this 8-K
Monopar Therapeutics filed this 8-K on June 1, 2021.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): June 1,
2021
MONOPAR
THERAPEUTICS INC.
(Exact name of registrant as specified in
its charter)
|
Delaware
|
|
001-39070
|
|
32-0463781
|
|
(State or other
jurisdiction of incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
1000
Skokie Blvd., Suite 350, Wilmette,
IL 60091
|
|
60091
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
(847)
388-0349
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the
Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
Common
Stock, $0.001 par value
|
|
MNPR
|
|
The
Nasdaq Stock Market LLC
(Nasdaq Capital Market)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§ 240.12b-2 of this chapter).
Emerging growth
company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☒
Item
7.01 Regulation FD Disclosure
On
June 1, 2021, Monopar Therapeutics Inc. issued a press release
announcing the appointment of
Andrew Cittadine, MBA, as Chief Operating Officer. In this role,
Mr. Cittadine will provide leadership and oversight of
Monopar’s global operations and business and development
strategy.
The
press release is furnished as Exhibit 99.1 to this report and
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
|
Exhibit No.
|
Description
|
|
99.1
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
Monopar
Therapeutics Inc.
|
|
|
|
|
|
|
|
|
Date: June 1,
2021
|
By:
|
/s/
Kim
R. Tsuchimoto
|
|
|
|
|
Name: Kim
R. Tsuchimoto
|
|
|
|
|
Title:
Chief
Financial Officer, Secretary and Treasurer
|
|
Monopar Therapeutics Expands
Leadership Team with Appointment of Andrew Cittadine as Chief
Operating Officer
WILMETTE,
Ill., June 1,
2021 – Monopar
Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company primarily focused on developing
proprietary therapeutics designed to extend life or improve the
quality of life for cancer patients, today announced the
appointment of Andrew Cittadine, MBA, as Chief Operating Officer.
In this role, Mr. Cittadine will provide leadership and oversight
of Monopar’s global operations and business and development
strategy.
Mr. Cittadine is an experienced healthcare executive and serial
entrepreneur with a successful track record of identifying,
founding, and building healthcare businesses from concept to
commercialization to acquisition by Fortune Global 1000 firms.
These include founding two successful diagnostic imaging companies,
Sensant Corp. and American Biooptics, and leading both through
acquisitions, by Siemens and Olympus, respectively. His
leadership experience also includes acting as startup CEO of a
critical care company, SonarMed, which was acquired by Medtronic.
He has managed manufacturing and quality systems implementation,
execution of multi-center clinical trials, and regulatory
clearances for new technologies in Europe and the US. Mr. Cittadine
received his BA, BS, and MS from Stanford and an MBA from
Northwestern’s Kellogg School of Management.
“We are very
pleased to welcome Andrew. He is a proven healthcare leader and a
strong addition to our executive team,” said Chandler Robinson, MD,
Chief Executive Officer of Monopar.
“This is an exciting time at Monopar. They have a
well-balanced and promising portfolio of earlier and later stage
drug candidates. I’m honored to join this talented and
committed team in developing these potentially life-changing
treatments for cancer patients,” said Mr.
Cittadine.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a
clinical-stage biopharmaceutical company primarily focused on
developing proprietary therapeutics designed to extend life or
improve the quality of life for cancer
patients. Monopar's pipeline consists
of Validive for the prevention of
chemoradiotherapy-induced severe oral mucositis in oropharyngeal
cancer patients; camsirubicin for the treatment of
advanced soft tissue sarcoma; and a late-stage preclinical
antibody, MNPR-101, for advanced cancers and severe COVID-19. For
more information, visit: www.monopartx.com.
Forward-Looking
Statements
Statements contained in this press release regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. The words “may,” “will,”
“could,” “would,” “should,”
“expect,” “plan,” “anticipate,”
“intend,” “believe,”
“estimate,” “predict,”
“project,” “potential,”
“continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Examples of these forward-looking
statements include the statement concerning the team developing
potentially life-changing treatments for cancer patients. The
forward-looking statements involve risks and uncertainties
including, but not limited to the requirement for additional
capital to complete preclinical and clinical development of
Monopar’s pipeline and the significant general risks and
uncertainties surrounding the research, development, regulatory
approval, and commercialization of therapeutics. Actual results may
differ materially from those expressed or implied by such
forward-looking statements. Risks are described more fully in
Monopar's filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were
made. Monopar undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made. Any forward-looking
statements contained in this press release represent
Monopar’s views only as of the date hereof and should
not be relied upon as representing its views as of any subsequent
date.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter:
@MonoparTx LinkedIn:
Monopar Therapeutics